International Journal of Pharmaceutics 2013-09-15

I. Technological approaches to improve the dissolution behavior of nateglinide, a lipophilic insoluble drug: nanoparticles and co-mixing.

Lauretta Maggi, Giovanna Bruni, Mariarosa Maietta, Andrea Canobbio, Andrea Cardini, Ubaldo Conte

Index: Int. J. Pharm. 454(1) , 562-7, (2013)

Full Text: HTML

Abstract

Nateglinide is a non-sulphonylurea insulinotropic oral antidiabetic agent. The main problem in formulating an oral dosage form is its low solubility in aqueous media. This problem is particularly critical for an anti-diabetic drug because it should be administered just before the meals and be quickly bioavailable to cover the post-prandial glycemic peak. In this work, some technological approaches have been studied to improve the dissolution rate of nateglinide. Furthermore, two different polymorphs of nateglinide (H and B) have been tested to evaluate the influence of the crystal habitus on the dissolution behavior of the drug. The results have clearly demonstrated that wettability plays a key role in the dissolution behavior of nateglinide. As a matter of fact the physical dispersion of the drug with colloidal silica or hydrophilic swellable polymers strongly enhances the dissolution rate of nateglinide. The two polymorphs tested did not show significant differences in terms of dissolution behavior. Copyright © 2013 Elsevier B.V. All rights reserved.


Related Compounds

Related Articles:

Formulation and in vitro evaluation of nateglinide microspheres using HPMC and carbopol-940 polymers by ionic gelation method.

2013-11-01

[Pak. J. Pharm. Sci. 26(6) , 1229-35, (2013)]

From evidence assessments to coverage decisions?: the case example of glinides in Germany.

2012-01-01

[Health Policy 104(1) , 27-31, (2012)]

Nateglinide--current and future role in the treatment of patients with type 2 diabetes mellitus.

2005-10-01

[Int. J. Clin. Pract. 59(10) , 1218-28, (2005)]

Efficacy and safety of mitiglinide versus nateglinide in newly diagnose patients with type 2 diabetes mellitus: a randomized double blind trial.

2012-02-01

[Diabetes Obes. Metab. 14(2) , 187-9, (2012)]

Nateglinide (Starlix): update on a new antidiabetic agent.

2003-01-01

[Int. J. Clin. Pract. 57(6) , 535-41, (2003)]

More Articles...